Biomapas has recently announced the opening of a new office in Stockholm, Sweden. This new location strengthens Biomapas’ presence in the Nordic countries and further accommodates the rapid growth of the company.
The expansion into the Nordics is in direct response to demand from Biomapas clients seeking local Regulatory and Pharmacovigilance support. The company already has offices in Switzerland, Lithuania, Russia, Georgia and Ukraine.
“We are delighted to announce the opening of our new office in Sweden. The decision to expand our presence into Nordic countries was a logical step in our business growth strategy,” said Audrius Sveikata, Chief Executive Officer at Biomapas. ”Although this expansion was primarily related to growing demand of our Regulatory and Pharmacovigilance solutions, Nordic Sponsors will also benefit from having a local contact and access to the large patient pool of Eastern Europe and the CIS region, where patient recruitment rates can be so much more reliable.”
Biomapas is a privately-owned contract research organization providing comprehensive clinical trial solutions for Phase I-IV clinical research and medical devices.
With its strong foothold in Eastern Europe and CIS countries, the company has a superb track record in patient recruitment. It is also well known for its extensive geographical reach in terms of on-the-ground regulatory and pharmacovigilance personnel. Biomapas employs an impressive team of experts, most of whom are either medical doctors (30%) or pharmacists (35%). With their diverse therapeutic expertise and thorough approach, they bring genuine value to Sponsors of clinical trials in terms of study design, regulatory support, study conduct and patient safety. The company has offices in Switzerland, Sweden, Lithuania, Georgia, Ukraine and Russia and has personnel in place to cover up to 64 countries.
Services range from first-in-human studies (with an impressive early phase unit in Vilnius, Lithuania) all the way up to product registration and post-approval support. Established in 2001, the company has gained experience of more than 190 clinical trials within numerous therapeutic fields including oncology, CNS, cardiovascular, infectious disease, immunology, rheumatology, pulmonology, endocrinology, gynecology, gastroenterology, nephrology, ophthalmology, urology and dermatology.